We remain very optimistic for the oncology market and its players after attending the ASCO (American Society of Clinical Oncology) 2015 in Chicago, the world’s most important oncology congress.
Its annual meeting is the biggest and most important oncology conference throughout the year. More than 30000 attendees got updates on clinical trials, evolving science and just about everything else around oncology. Immunooncology (IO) was the key theme at the conference with very promising developments. However, new therapies are also needed for patients not responding to IO treatments.
The MSCI World Healthcare NR Index gained 3.0% in June, while the MSCI World NR Index rose 1.5%. The decline in 10-year yields provided a booster shot to growth stocks, relative to their value peers. It is likely that the next months will continue to be dominated by debates on Fed and interest rates topics, and related growth/value factor pivots. More clarity on tapering can be expected after the summer break and the Jackson Hole summit.
Kieger AG is a main sponsor of the ”Swiss Sustainable Investment Market Study 2021”. This sponsored page by our Kieger Healthcare Portfolio Managers Urban Fritsche and Dr. Maria Specogna discusses: “Covid-19: a trigger for impact investors in global healthcare”.
In May, Healthcare gained 2.1%, while Global Equities rose 1.6%. The shift into value at the expense of growth and momentum continued over the past weeks, with Energy, Financials and Materials posting the top performances. IT returns, given the sector’s growth characteristics, were again subdued.